Previous close | 2.8800 |
Open | 2.8800 |
Bid | 2.8700 x 100 |
Ask | 3.0200 x 100 |
Day's range | 2.8700 - 3.0600 |
52-week range | 1.5000 - 3.9000 |
Volume | |
Avg. volume | 219,663 |
Market cap | 370.656M |
Beta (5Y monthly) | 1.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Wednesday, Immutep Limited (NASDAQ:IMMP) released preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression. The investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9% and diseas
Immutep Limited ( ASX:IMM ) is possibly approaching a major achievement in its business, so we would like to shine some...
In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy Now. With a market capitalization of $1.5 trillion, the Australian stock exchange, […]